ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded up 13.9% during mid-day trading on Thursday . The company traded as high as GBX 3.98 and last traded at GBX 3.98. 1,159,174 shares changed hands during mid-day trading, a decline of 53% from the average session volume of 2,466,091 shares. The stock had previously closed at GBX 3.50.
ImmuPharma Trading Down 15.1%
The firm has a 50-day moving average of GBX 3.85 and a 200 day moving average of GBX 4.43. The company has a market cap of £21.09 million, a P/E ratio of -9.14 and a beta of 3.01.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 633.14%. On average, equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- MarketBeat Week in Review – 09/14 – 09/18
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
